Clinical trial
A Dose-escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients With Relapsed or Refractory Hematologic Malignancies (Phase 1)
NCT01344876 is registered in ClinicalTrials.gov with Otsuka Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Dose-escalation Trial to Investigate the Safety and Tolerability of OPB-51602 in Patients With Relapsed or Refractory Hematologic Malignancies (Phase 1)
- Lead sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- April 30, 2011
- Completion date
- April 30, 2014
- Enrollment
- 20 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoid leukemia, acute myeloid leukemia, chronic myeloid leukemia, multiple myeloma, non-hodgkin lymphoma